Clinical Trials · NCT05443191
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 50
- Start date
- Oct 2022
- Locations
- 3 sites, Finland, France
- Primary endpoint
- Change in Glycated haemoglobin (HbA1c )